TCL Archive Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint November 25, 2011
TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012
TCL Archive In Brief: Hew Finally Okays New NIH Study Section For Chemical, Environmental Carcinogenesis March 16, 1979
TCL Archive DOD Seeks to Fund Innovative Research In 438 Million Prostate Cancer Program August 22, 1997